Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Symptoms and General Pathology

Digestive System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Stomach Neoplasms

Prostatic Neoplasms

Carcinoma

Carcinoma, Squamous Cell

Squamous Cell Carcinoma of Head and Neck

Lung Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Esophageal Neoplasms

Pancreatic Neoplasms

Sarcoma

Urinary Bladder Neoplasms

Uterine Cervical Neoplasms

Melanoma

Carcinoma, Renal Cell

Endometrial Neoplasms

Prostatic Neoplasms, Castration-Resistant

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Adenocarcinoma

Endocrine Gland Neoplasms

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Uterine Neoplasms

Uterine Diseases

Urologic Neoplasms

Urologic Diseases

Male Urogenital Diseases

Kidney Neoplasms

Kidney Diseases

Head and Neck Neoplasms

Pancreatic Diseases

Genital Neoplasms, Male

Genital Diseases, Male

Prostatic Diseases

Stomach Cancer

Small Cell Lung Cancer

Ovarian Cancer

Ovarian Epithelial Cancer

Esophageal Cancer

Pancreatic Cancer

Soft Tissue Sarcoma

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

MGC026 Dose Escalation

MGC026 Dose for Expansion

Global Trial Manager

Denise Casey, MD

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study.

Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.

A Study of MGC026 in Participants With Advanced Solid Tumors

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

The objective response rate (ORR) per RECIST v1.1 is estimated as the proportion of participants in the Response Evaluable population who achieve best overall response of complete response (CR) or partial response (PR) (called responders). Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) is used to classify responses.

DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented progression or death from any cause, whichever occurs first. (RECIST 1.1) is used to classify responses.

The ORR per Prostate Cancer Working Group 3 (PCWG3) criteria is estimated as the proportion of participants in the Response Evaluable population who achieve best overall response of CR or PR (called responders).

DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented progression, per PCWG3 criteria or death from any cause, whichever occurs first.

The maximum concentration in the bloodstream at the end of the infusion.

Development of anti-MGC026 antibodies in the bloodstream

MacroGenics

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of MGC026 in Participants With Advanced Solid Tumors	NCT06242470	Advanced Solid ... Advanced Cancer Metastatic Canc... Squamous Cell C... Non Small Cell ... Small-cell Lung... Bladder Cancer Sarcoma Endometrial Can... Melanoma Castration Resi... Cervical Cancer Colorectal Canc... Gastric Cancer Gastro-esophage... Pancreas Cancer Clear Cell Rena... Hepatocellular ... Platinum-resist...	MGC026 Dose Esc... MGC026 Dose for...	18 Years -	MacroGenics
A Study of MGC026 in Participants With Advanced Solid Tumors	NCT06242470	Advanced Solid ... Advanced Cancer Metastatic Canc... Squamous Cell C... Non Small Cell ... Small-cell Lung... Bladder Cancer Sarcoma Endometrial Can... Melanoma Castration Resi... Cervical Cancer Colorectal Canc... Gastric Cancer Gastro-esophage... Pancreas Cancer Clear Cell Rena... Hepatocellular ... Platinum-resist...	MGC026 Dose Esc... MGC026 Dose for...	18 Years -	MacroGenics
A Study of MGC026 in Participants With Advanced Solid Tumors	NCT06242470	Advanced Solid ... Advanced Cancer Metastatic Canc... Squamous Cell C... Non Small Cell ... Small-cell Lung... Bladder Cancer Sarcoma Endometrial Can... Melanoma Castration Resi... Cervical Cancer Colorectal Canc... Gastric Cancer Gastro-esophage... Pancreas Cancer Clear Cell Rena... Hepatocellular ... Platinum-resist...	MGC026 Dose Esc... MGC026 Dose for...	18 Years -	MacroGenics

Spots Global Cancer Trial Database for mgc026 dose escalation